Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Slideshows|February 5, 2020
Hypertension Prevalence Among Adults
Author(s)Sydney Jennings
From 2013-2016, about 46% of US adults had hypertension. Plus more highlights from the AHA's annual Heart Disease and Stroke Statistical Update.
Advertisement
The American Heart Association's annual report titled, "
The report is a critical resource for patients, physicians, and others seeking accurate data.
Scroll through our quick slideshow below for key points from the chapter on hypertension, focusing on prevalence among US adults.
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Advertisement
Advertisement
Trending on Patient Care Online
1
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
2
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
3
Long-Term and Real-World Safety Data on Antipsychotic Agitation Therapy
4
Mechanism and Trial Data for an Antipsychotic Agitation Therapy
5